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CObjectives: Patients receiving enoxaparin are at risk of bleeding. The
study of the economic impact of enoxaparin-associated bleeding in
Asian population, however, is limited. This study aimed to estimate the
attributable costs and length of stay (LOS) of patients experiencing
enoxaparin-associated bleeding compared with nonbleeding patients
in the setting of acute coronary syndrome. Methods: We conducted a
retrospective cohort study of hospitalized patients with acute coronary
syndromewho received enoxaparin in a large university-affiliated hos-
pital. Cost and LOS were compared among three groups of patients
according to the status of bleeding event. The attributable cost and
LOS were estimated by using multiple linear regressions with log-
transformed model and adjusted by confounders. The adjusted
means of cost and LOS estimates were retransformed to their natu-
ral values by using Duan’s smearing estimator. The differences of
costs and LOS were presented as mean with 95% confidence inter-
vals (CIs). Results: Out of 346 patients, 134 experienced enoxaparin- O
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doi:10.1016/j.vhri.2012.03.011ssociated bleeding (28 and 106 patients experienced major and minor
leeding, respectively). The average age and gender in both groups
ere similar. Compared to the nonbleeding group, the attributable cost
nd LOS were 108,226 Thai baht (95% CI: 87,068–129,386) and 8 days
95% CI: 7.1–9.0) for major bleeding and 72,997 Thai baht (95% CI:
7,822–88,172) and 3.1 days (95% CI: 2.5–3.7) for minor bleeding,
espectively. Conclusions: Bleeding is significantly associated with in-
reased cost and LOS among enoxaparin users. These findings suggest
hat strategies aiming to reduce bleeding events may potentially help
educe the cost of care among patients with acute coronary syndrome
eceiving enoxaparin therapy.
eywords: acute coronary syndrome, bleeding, cost, enoxaparin, length
f stay.
opyright © 2012, International Society for Pharmacoeconomics and
utcomes Research (ISPOR). Published by Elsevier Inc.Introduction
Enoxaparin is a low-molecular-weight heparin (LMWH) derived
from unfractionated heparin through chemical or enzymatic de-
polymerization. Compared with unfractionated heparin in the
treatment of venous thromboembolism and acute coronary syn-
drome (ACS), LMWHs provide greater effectiveness without an in-
creased risk of complications [1,2].
ACS isacardiacconditionthatcan leadtomyocardial infarctionand
death [3]. LMWHsare currently recommendedasan important compo-
nent in the management of ACS and have superseded unfractionated
heparin in this regard [4]. Enoxaparin has become the LMWHof choice
in this setting due to a large body of supportive evidence [4–8].
Despite this proven efficacy, bleeding complications are still of
particular concern in patients who receive enoxaparin therapy [9].
Major bleeding is clinically more important because it has been
shown to be an independent predictor of short- and long-term
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Published by Elsevier Inc.mortality in patients with ACS and was associated with increased
cost and a longer duration of hospital stay [10–12].
Although there are numerous studies [13,14] evaluating the
impact of bleeding in terms of clinical consequences, extended
stays in hospital, and increasing costs of care, there is currently a
lack of such data from Asian countries where the management of
ACS can be quite different from that in the Western world. This
study therefore aimed to estimate the attributable costs and
length of stay (LOS) of Thai patients experiencing enoxaparin-as-
sociated bleeding compared with nonbleeding patients.
Methods
Setting, patient sample, and data collection
All cases of patients with ACS who were admitted at a large uni-
versity-affiliated hospital in Bangkok, Thailand, during January
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tively reviewed. In case of patients experiencing more than one
admission, the most recent admission was considered. The inclu-
sion criteria were 1) age 18 years or older, 2) having a diagnosis of
ACS, and 3) receiving at least one dose of enoxaparin.We excluded
patients from our analysis if they met the following criteria: 1)
enoxaparin dose, dosing interval, date of birth, serum creatinine,
or weight values were missing; 2) pregnancy; 3) burn; 4) hemo-
philia A or B, von Willebrand’s disease, hereditary hemorrhagic
telangiectasis, idiopathic thrombocytopenic purpura, thrombocy-
topenia, dengue, hemorrhagic fever, antithrombin III deficiency;
and 5) thrombocytopenia (platelet count 50,000 cells/mL or lower).
All medical records meeting the above criteria were reviewed by
using a standardized data collection form.
We defined enoxaparin-associated bleeding as the bleeding
that occurred during enoxaparin therapy or within 24 hours fol-
lowing the discontinuation of enoxaparin therapy. For patients
who experienced more than one bleeding episode, only the most
severe bleeding episode was considered.
This study protocolwas approved by the Committee onHuman
Rights Related to Researches Involving Human Subjects, Faculty of
Medicine, Ramathibodi Hospital.
Statistical analyses
Patients were categorized into three groups according to the
status of an inhospital bleeding event as 1) nonbleeding, 2) ma-
jor bleeding, and 3) minor bleeding based on Thai Acute Coro-
nary Syndrome Registry (TACSR) major bleeding classification
[15]. Major bleeding, defined by TACSR, is an overt clinical
bleeding (or documented intracranial or retroperitoneal hemor-
rhage) requiring blood transfusion or associated with a drop in
hemoglobin of greater than 5 g/dL or in hematocrit of greater
than 15%. Baseline characteristics were compared by using the
chi-square test for categorical variables and the analysis of vari-
ance test or the Kruskal-Wallis rank test for continuous vari-
ables as appropriate. A P value of 0.05 was considered statis-
tically significant.
Cost and LOS were compared among the three groups by using
multivariable linear regression analysis and included baseline pa-
tient characteristics and presenting sign and symptom as covari-
ates. The criteria for retention variables in themodelwas based on
clinical predictors and a P value of 0.25. The cost variable was
log-transformed prior to analysis to correct for skewness [16,17].
After analysis using multivariable linear regression, it was re-
transformed to their natural values by using Duan’s smearing es-
timator [16,18].
Sensitivity analysis
To evaluate the robustness of our analysis, we performed sensi-
tivity analysis of cost and LOS stratified by patient groups on the
basis of two standard bleeding severity classification systems. The
first was a clinically based scale, Global Use of Strategies to Open
Occluded Coronary Arteries criteria [19], and the second was a
laboratory-based scale, Thrombolysis inMyocardial Infarction cri-
teria [20].
Results
Of 346 patients enrolled in this study, the majority were admitted
because of non-ST-segment elevation myocardial infarction
(NSTEMI) (n  196; 57%) followed by ST-segment elevation myo-
ardial infarction (STEMI) (n  87; 25%) and unstable angina (UA)
(n  63; 18%) (Fig. 1). There were 212 (61%) patients who did not
experience any bleeding events while 28 (8%) and 106 (31%) pa-
tients experienced major and minor bleeding, based on TACSR
classification, respectively. Demographic data of the patients ineach groupwere comparable with regard to age and sex. However,
some variables were different such as the presence of diabetes
mellitus and the degree of renal function (Table 1).
After adjustment for potential confounders, ACS patients with
major bleeding had a significant increase in total cost of care
(108,226 Thai bhat [THB]; 95% confidence interval [CI] 87,068–
129,386; P  0.001) and LOS (8 days; 95% CI 7.1–9.0; P  0.001)
compared with those without a bleeding event (Table 2). For ACS
patients with a minor bleeding event, the attributable cost and
LOS was 72,997 THB (95% CI 57,822– 88,172; P 0.031) and 3.1 days
(95%CI 2.5–3.7; P 0.001), respectively (Table 2). It should be noted,
however, that the mortality rate was 42.8% (12 of 28), 12.3% (13 of
106), and 2.4% (5 of 212) in major, minor, and nonbleeding groups,
respectively.
Sensitivity analysis (Table 3) was performed to investigate the
robustness of the results. Despite changing the bleeding definition
by using Global Use of Strategies to Open Occluded Coronary Ar-
teries and Thrombolysis in Myocardial Infarction criteria, the es-
timated cost and LOS showed similar trends, indicating that the
higher the severity of bleeding, the higher the cost and LOS ob-
served. There is an exception for severe bleeding group in Global
Use of Strategies to Open Occluded Coronary Arteries criteria and
major bleeding group in Thrombolysis in Myocardial Infarction
criteria; the estimated cost and LOSwere lower than other groups.
This finding is most likely a result of small number of patients in
these groups and premature death experienced by these patients.
Discussion
ACShas nowbecomeaworldwide problem [3,7,8,15]. The econom-
ical impact of ACS management would likely post a huge burden
on health care spending on these countries [21,22]. This was illus-
trated not only in this study but also in a recent study that found
that the average cost of care for a patient with ACS is approxi-
mately 120,000 THB per admission, with around 71million THB for
Fig. 1 – Porportion of acute coronary syndrome patients
included in the study. STEMI, ST-segment elevation
myocardial infarction; NSTEMI, non-ST-segment elevation
myocardial infarction; UA, unstable angina.all Thai patients with ACS during the first year of therapy [22].
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impact of therapies aiming to treat ACS should not be ignored.
Based on our study, the impact of bleeding associated with
enoxaparin is staggering. In fact, the cost of enoxaparin-associ-
ated bleeding is estimated to be as high as half (major bleeding)
and one-third (minor bleeding) of the average cost of ACS care per
patient (Table 2). In addition, the attributable cost of bleeding in
our study, compared with the no-bleeding group, is similar to that
found in a previously published study that was conducted in Thai
population, at approximately 100,000 THB per admission [21].
With approximately 50,000 cases of ACS each year, the actual na-
tionwide impact of the cost and LOS of enoxaparin-associated
bleeding should be an important agenda for the Thai health care
system to deal with.
Our finding was consistent with other studies that the higher
the severity of bleeding, the higher the cost and LOS observed
[14,23,24]. Variation in bleeding rates, however, could be affected
by differences in certain patient characteristics, pattern of medi-
cation uses, and frequency or popularity of percutaneous coronary
intervention in each country. Cost of care in different countries
also varies widely on the basis of distinct socioeconomic condi-
Table 1 – Patients’ characteristics.
Characteristics Major blee
(n  28
Demographics
Age (y), mean  SD 68.6  12
65 17 (60.
75 10 (35.
Male sex 13 (46.
Medical history
Previous bleeding 5 (17.
Previous stroke 2 (7.1
Diabetes mellitus 21 (75.
Hypertension 23 (82.
Presenting signs/symptom
Creatinine clearance (mL/min), median (IQR) 38.1 (33.
Congestive heart failure at admission 15 (53.
Treatment
Conservative 21 (75.
Invasive 7 (25.
PCI 6 (21.
CABG 1 (3.6
Note. Numbers shown are number and percentages unless indicated
CABG, coronary artery bypass grafting; CrCl, creatinine clearance; IQ
* Compared with invasive treatment.
Table 2 – Cost and length of stay in three groups of patient
bleeding, hypertension, stroke, CrCl, DM, CHF, and enoxap
Outcomes Major bleeding
(n  28)
M
Total cost (THB) 228,061 (206,334–249,788) 192,
Attributable cost* 108,226† (87,068–129,386) 72,9
LOS (d) 16.4 (15.3–17.5) 1
Attributable LOS* 8.0† (7.1–9.0)
Note. Numbers shown are mean and 95% confidence interval unless
ACS, acute coronary syndrome; CrCl, creatinine clearance; DM, diabe
baht.
* Attributable cost and attributable LOS were compared with the no-
† P  0.001.
‡ P  0.031.tions that are specific to each country. In the United States, a ret-
rospective study among patients with ACS in a real-world setting
[24] reported that the incidence of major bleeding events was
slightly higher (9% vs. 8%) than that in our study. These may be
due to the higher use of the coronary artery bypass grafting pro-
cedure (26.3%) and prior bleeding (36%) compared with that in our
study. After adjusting for patient characteristics, patients with se-
vere bleeding incurred initial hospitalization charges that were
$48,114 higher than those of patients without bleeding (P 0.001).
n Europe, Bufe et al. [23] estimated the costs to manage bleeding
omplications in patients with ACS experiencing a decrease in
emoglobin, puncture site, or bleeding requiring transfusion by
sing retrospective chart review in hospitals in France, Germany,
taly, Spain, and Sweden. The investigators found that the average
OS and costs ranged between 7.7 and 11.3 days and €3,986 and
10,252, respectively. Of these, patients receiving transfusions due
o bleeding events incurred the highest LOS. These findings are
imilar to those we found for minor bleeding events (Table 2). The
easons might be attributable to the bleeding definition that in
he study by Bufe et al. was less severe than the major bleeding
efined by the TACSR classification we used. A number of studies
Minor bleeding
(n  106)
No bleeding
(n  212)
P
66.8  12.7 66.9  11.5 0.757
57 (53.8) 120 (56.6) 0.780
33 (31.1) 54 (25.5) 0.366
43 (40.6) 63 (29.7) 0.060
21 (19.8) 27 (12.7) 0.237
19 (17.9) 31 (14.6) 0.352
47 (44.3) 106 (50.0) 0.015
83 (78.3) 156 (73.6) 0.463
37.9 (33.9) 18.4 (15.8) 0.001
54 (50.9) 89 (41.9) 0.217
56 (52.8) 138 (65.1) 0.036*
50 (47.2) 74 (34.9) —
42 (39.6) 56 (26.4) 0.031
8 (7.6) 18 (8.5) 0.598
rwise.
erquartile range; PCI, percutaneous coronary intervention.
th ACS after adjusting for age, sex, and history of
dosage received.
r bleeding
 106)
No bleeding
(n  212)
P
76,728–208,935) 119,835 (112,649–127,019) 0.001
7,822–88,172) Reference group —
0.9–11.9) 8.4 (8.0–8.7) 0.001
.5–3.7) Reference group —
ated otherwise.
ellitus; CHF, congestive heart failure; LOS, length of stay; THB, Thai
ing group.ding
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ciated bleeding [9,11,12,15]. Common bleeding risk factors identi-
fied were advanced age, impaired renal function, use of multiple
antithrombotic therapies, and excessive dosing.With such knowl-
edge, care should be taken when prescribing enoxaparin to those
patients while strict adherence toward recommended dosing
should also be implemented to achieve the goal of cost saving due
to bleeding reduction.
The strength of this study is based on a compliance with rigor-
ous methodology used for analyzing observational data. Because
cost variables are usually not normally distributed, we performed
log-transforming of cost data to achieve linearity, normalizing the
residuals or stabilizing their variance [17]. Then, we analyzed the
data by using multivariable linear regression of the log scale ad-
justed for potential confounders and retransformed to their natu-
ral values by using Duan’s smearing estimator [18]. Fortunately, in
this study, log cost was normally distributed and there was no
evidence of heteroscedasticity. In this case, the smearing retrans-
formation after multivariable regression is reliable and obtains
efficiency gains over the estimation of ordinary least squares re-
gression on untransformed cost [16].
Several limitations of this study should be noted. First, baseline
characteristics of the patients in the major bleeding group are
somewhat different from those of other groups. Several parame-
ters might be associated with the increased risk of bleeding. For
example, advanced age, history of diabetes, history of hyperten-
sion, and severe renal failure; although they were not statistically
significant different among groups, a higher proportion in thema-
jor bleeding group was observed. These may affect the estimation
of the outcomes.We have attempted, however, our best to control
for these potential confounders by using multivariable analyses.
Second, some patients in our analysis were prematurely dead,
which might distort the estimations of the cost and LOS. Patients
dying shortly after entering a study often used less resources,
whereas those who remain alive for a time but eventually die are
among the most expensive [25]. Some investigators have applied
standard survival analysis methods such as Kaplan-Meier estima-
tors, log-rank tests, and Cox regression to the problem of cost
evaluation under censoring, by analyzing censored costs as
though theywere censored survival times [25]. But, this strategy is
Table 3 – Total cost and length of stay in patients with
ACS based on GUSTO and TIMI criteria after adjusting
for age, sex, and history of bleeding, hypertension, CrCl,
DM, CHF, and enoxaparin dosage received.
Patient groups Cost (THB) LOS (d)
GUSTO criteria
Severe (n  4) 77,026 (52,815–101236) 2.8 (0.8–4.7)
Moderate (n  23) 269,675 (239639–299709) 18.3 (17.1–19.6)
Mild (n  107) 192,211 (175,930–208,492) 11.6 (11.1–12.1)
No bleeding
(n  212)
118,937 (111,678–126,196) 8.3 (8.0–8.7)
TIMI criteria
Major (n  4) 201,192 (138,399–263,984) 10.5 (7.7–13.3)
Minor (n  12) 297,340 (241,145–353,536) 14.2 (12.4–15.9)
Minimal (n  120) 194,918 (180,201–209,635) 12.4 (11.8–12.7)
No bleeding
(n  210)
118,365 (111,287–125,442) 8.3 (7.9–8.7)
Note. Numbers shown are mean and 95% confidence interval un-
less indicated otherwise.
ACS, acute coronary syndrome; CHF, congestive heart failure; CrCl,
creatinine clearance; DM, diabetes mellitus; GUSTO, Global Use of
Strategies to Open Occluded Coronary Arteries; THB, Thai baht;
TIMI, Thrombolysis in Myocardial Infarction; LOS, length of stay.generally invalid [25,26]. Even though there was no clear guidanceon when the problem due to censored data became an important
issue in cost analysis, the rule of thumb of 10% was widely known
that the mortality rate less than 10% was unlikely to affect the
overall findings [27]. In our study, themortality rate was only 8.7%
(30 of 316 patients); therefore, it is less likely to have an impact on
the study results.
Third, we did not have actual cost; however, cost to charge
ratio should be acceptable. In addition, we did not undertake so-
cietal perspective. It means that we have not taken direct non-
medical cost (i.e., cost of transportation of their relatives, etc.) and
indirect cost (i.e., cost associated with loss of productivity) into
account. If we include such costs, it will likely result in a larger
estimate of total costs. Last, the results were derived from a uni-
versity-based hospital setting. This might not be generalizable to
other levels of health care settings.
Our study provides the estimates of attributable cost and LOS
associated with enoxaparin-associated bleeding. Their large mag-
nitude prompts clinicians and policymakers to paymore attention
to this preventable adverse event. The cost estimates from this
study could be used as important input parameters in assessing
the cost-effectiveness of interventions used to reduce the risk of
enoxaparin-associated bleeding.
Conclusions
In summary, LMWHs, an important component for ACS manage-
ment, are not without risk. Bleeding associatedwith enoxaparin is
associated with a significant increase in the cost of care and LOS.
With increasing number of ACS cases in the developing countries,
health care policymakers should be aware of this important issue.
In addition, strategies aimed to reduce such adverse effects should
be widely implemented tomaximize the benefit andminimize the
unnecessary loss of health care spending.
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